Alnylam secures $79.79 million through private placement of its shares

Stock sold at $93.17 each and $95.00 each to Genzyme through offering

By Devika Patel

Knoxville, Tenn., Jan. 27 – Alnylam Pharmaceuticals, Inc. settled an $18.29 million private placement of stock with Genzyme Corp. on Jan. 22, according to an 8-K filed Tuesday with the Securities and Exchange Commission. The company also completed a $450 million public offering of stock on Jan. 20 and another $61.51 million placement with the investor on Jan. 26.

In the Jan. 22 placement, Alnylam sold 196,251 common shares at $93.17 per share. The price per share is a 6.65% premium to $87.36, the Jan. 21 closing share price. On Jan. 26, the investor bought 647,448 shares at $95.00 apiece, which is a 1.69% premium to the Jan. 23 closing share price of $93.42.

In the public sale, the company raised $450 million by selling 4,736,842 common shares at $95.00 apiece through representative underwriters J.P. Morgan Securities LLC and Deutsche Bank Securities Inc.

Based in Cambridge, Mass., Alnylam is a biopharmaceutical company focused on RNA interference technology.

Issuer:	Alnylam Pharmaceuticals, Inc.
Issue:	Common stock
Amount:	$79,792,266
Shares:	843,699
Price:	$93.17 (for 196,251 shares on Jan. 22), $95.00 (for 647,448 shares on Jan. 26)
Warrants:	No
Investor:	Genzyme Corp.
Settlement date:	Jan. 22 (for $18,284,706), Jan. 26 (for $61,507,560)
Stock symbol:	Nasdaq: ALNY
Stock price:	$87.36 at close Jan. 21, $93.42 at close Jan. 23
Market capitalization:	$7.37 billion

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.